Assessment of the Enzymuria Resulting from Gentamicin Alone and Combinations of Gentamicin with Various β-Lactam Antibiotics

Abstract

Spanish

French

OBJECTIVE:

To determine the propensity of β-lactam antimicrobials to ameliorate or potentiate aminoglycoside-induced renal enzymuria.

DESIGN:

Two open, randomized, double-blind, parallel-group studies were conducted in young, healthy, male volunteer subjects. Using a common protocol, 24-hour urine collections were analyzed for the renal tubular enzymes alanine aminopeptidase (AAP) and N-acetyl-β-d-glucosaminidase (NAG), as well as for creatinine. Antimicrobial combinations studied included gentamicin plus placebo and gentamicin plus ticarcillin/clavulanate (protocol 1); and gentamicin plus placebo, gentamicin plus piperacillin, and gentamicin plus ceftazidime (protocol 2). The antimicrobial regimens were administered for 7 days. Eight subjects completed each treatment group.

RESULTS:

There were no significant differences between treatment groups with regard to urine creatinine excretion or serum gentamicin concentrations in either protocol. Enzymuria (AAP [p = 0.039] and NAG [p = 0.337]) was decreased in the gentamicin plus ticarcillin/clavulanate treatment compared with that in the gentamicin plus placebo treatment. Increased enzymuria, as indicated by increased urine concentrations of AAP and NAG, was observed in the gentamicin plus ceftazidime treatment (p < 0.05) compared with the other two treatments.

CONCLUSIONS:

Based on relative enzymuria, ticarcillin/clavulanate may be renal protective. Piperacillin neither potentiated nor ameliorated aminoglycoside-induced enzymuria. Since acute elevations in AAP and NAG reflect insults to the kidney, these studies suggest that ceftazidime may enhance aminoglycoside- induced renal injury. Piperacillin had no effect on enzymuria and would appear not to enhance or protect against aminoglycoside- induced renal injury.

Keywords

nephrotoxicity enzymuria ceftazidime ticarcillin/clavulanate β-lactam gentamicin

Get full access to this article

View all access options for this article.

References

De Broe

Giuliano

Verpooten

. Aminoglycoside nephrotoxicity: Mechanism and prevention. Adv Exp Med Biol 1989; 252: 233–45.

Molitoris

Meyer

Dahl

Geerdes

. Mechanism of ischemia-enhanced aminoglycoside binding and uptake by proximal tubule cells. Am J Physiol 1993; 264: F907–16.

Thomas

Toutain

Dadoun

Morin

Fillastre

. Can piperacillin modify the experimental nephrotoxicity of gentamicin? Presse Med 1986; 15: 2362–7.

Gibey

Dupond

Henry

. Urinary N-acetyl-beta-d-glucosaminidase (NAG) isoenzyme profiles: A tool for evaluating nephrotoxicity of aminoglycosides and cephalosporins. Clin Chim Acta 1984; 137: 1–11.

Goldstein

Smith

Tarloff

Contardi

Rush

Hook

. Minireview: Biochemical mechanisms of cephaloridine nephrotoxicity. Life Sci 1988; 42: 1809–16.

Mondorf

. Comparative studies on the action of aminoglycosides and cephalosporins on the proximal tubule of the human kidney. Nouv Presse Med 1978; 7: 3835–7.

Mondorf

. Effect of cefoperazone alone and in combination with tobramycin on the proximal tubular membrane of the human kidney. Infection 1981; 9 (Suppl 1):S30–3.

Tune

. Mechanism of the mitochondrial respiratory toxicity of cephalosporin antibiotics. Adv Exp Med Biol 1989; 252: 313–8.

Tune

Hsu

. Toxicity of cephaloridine to carnitine transport and fatty acid metabolism in rabbit renal cortical mitochondria: Structure-activity relationships. J Pharmacol Exp Ther 1994; 270: 873–80.

10.

Barza

. The nephrotoxicity of cephalosporins: An overview. J Infect Dis 1978; 137 (suppl):S60–73.

11.

Mannion

Bloch

Popovich

. Cephalosporin-aminoglycoside synergistic nephrotoxicity: Fact or fiction? Drug Intell Clin Pharm 1981; 15: 248–56.

12.

Schentag

Plaut

Cerra

Wels

Walczak

Buckley

. Aminoglycoside nephrotoxicity in critically ill surgical patients. J Surg Res 1979; 26: 270–9.

13.

Schentag

. Specificity of renal tubular damage criteria for aminoglycoside nephrotoxicity in critically ill patients. J Clin Pharmacol 1983; 23: 473–83.

14.

Mondorf

Heynold

Scherberich

Hess

Schoeppe

. Assessment of the nephrotoxic potential of ceftazidime and a ceftazidime/tobramycin combination in volunteers. Infection 1983; 11 (Suppl 1):S57–62.

15.

Mondorf

Scherberich

Heinert

Schoeppe

. Enzymuria: A parameter for the assessment of potential nephrotoxicity of cephalosporins. J Antimicrob Chemother 1983; 12 (Suppl A):251–4.

16.

Mondorf

Zegelman

Klose

Maske

Scherberich

Stefanescu . Effects of various cephalosporins on the proximal tubule of the human kidney. Eur J Clin Pharmacol 1978; 13: 357–63.

17.

Mondorf

Breier

Hendus

Sherberich

MaCkenrodt

Shah

. Effect of aminoglycosides on proximal tubular membranes of the human kidney. Eur J Clin Pharmacol 1978; 13: 133–42.

18.

Sanderink

Artur

Siest

. Human aminopeptidases: A review of the literature. J Clin Chem Clin Biochem 1988; 26: 795–807.

19.

Eliopoulos

. Therapy of enterococcal infections. Eur J Clin Microbiol 1990; 9: 118–26.

20.

Ceftazidime combined with a short or long course of amikacin for empirical therapy of gram negative bacteremia in cancer patients with granulocytopenia. The EORTC International Antimicrobial Therapy Cooperative Group. N Engl J Med 1987; 317: 1692–8.

21.

Moore

Smith

Lietman

. The association of aminoglycoside plasma levels with mortality in patients with gram negative bactermia. J Infect Dis 1984; 149: 443–8.

22.

Vemuri

Zervos

. Enterococcal infection: The increasing threat of nosocomial spread and drug resistance. Postgrad Med 1993; 93: 121–8.

23.

Wade

Petty

Conrad

Smith

Lipsky

Ellner

. Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus an aminoglycoside. Lancet 1978; 2: 604–6.

24.

Klastersky

Hensgens

Debusscher

. Empiric therapy for cancer patients: Comparative study of ticarcillin—tobramycin, ticarcillin—cephalothin, and cephalothin—tobramycin. Antimicrob Agents Chemother 1975; 7: 640–5.

25.

Stein

Mummaw

Dobra

Sleight

. Amelioration of gentamicin nephrotoxicity with carbenicillin and piperacillin (abstract). J Clin Pharmacol 1989; 29: 833.

26.

Trollfors

Alestig

Rodjer

Sandberg

Westin

. Renal function in patients treated with tobramycin—cefuroxime or tobramycin—penicillin G. J Antimicrob Chemother 1983; 12: 641–5.

27.

Mondorf

Bonsiepe

Mondorf

. Randomized multi center study comparing nephrotoxicity of ceftazidime versus the combination of piperacillin and netilmicin with and without furosemide. Adv Exp Med Biol 1989; 252: 307–12.

28.

Verho

Maab

Malerczyk

Grotsch

. Renal tolerance of cefpirome (HR 810) a new cephalosporin antibiotic. Infection 1987; 15: 215–9.

29.

Wellwood

Price

Ellis

Thompson

. A note on the practical aspects of the assay of N-acetyl-β-d-glucosaminidase in human urine. Clin Chim Acta 1976; 69: 85–91.

30.

Maruhn

. Rapid colorimetric assay of beta-galactosidase and N-acetyl-beta-glucosaminidase in human urine. Clin Chim Acta 1976; 73: 453–61.

31.

Jung

Scholz

. An optimized assay of alanine aminopeptidase activity in urine. Clin Chem 1980; 26: 1251–4.

32.

Bennett

Wood

Houghton

Gilbert

. Modification of experimental aminoglycoside nephrotoxicity. Am J Kidney Dis 1986; 8: 292–6.

33.

Sabra

Branch

. Role of sodium in protection by extended-spectrum penicillins against tobramycin-induced nephrotoxicity. Antimicrob Agents Chemother 1990; 34: 1020–5.

34.

English

Gilbert

Kohlhepp

Kohnen

Mayor

Houghton

. Attenuation of experimental tobramycin nephrotoxicity by ticarcillin. Antimicrob Agents Chemother 1985; 27: 897–902.

35.

Hale

Jenkins

Matsen

. In vitro inactivation of aminoglycoside antibiotics by piperacillin and carbenicillin. Am J Clin Pathol 1980; 74: 316–9.

36.

Blair

Duggan

Schroeder

. Inactivation of amikacin and gentamicin by carbenicillin in patients with end-stage renal failure. Antimicrob Agents Chemother 1982; 22: 376–9.

37.

Schentag

Simons

Schultz

Vance

Williams

. Complexation versus hemodialysis to reduce elevated aminoglycoside serum concentrations. Pharmacotherapy 1984; 4: 374–80.

38.

Williams

Hottendorf

Bennett

. Inhibition of renal membrane binding and nephrotoxicity of aminoglycosides. J Pharmacol Exp Ther 1986; 237: 919–25.

39.

French

Cerra

Plaut

Schentag

. Amikacin and gentamicin accumulation pharmacokinetics and nephrotoxicity in critically ill patients. Antimicrob Agents Chemother 1981; 19: 147–52.

40.

De Broe

Verbist

Verpooten

. Influence of dosage schedule on renal cortical accumulation of amikacin and tobramycin in man. J Antimicrob Chemother 1991; 27 (Suppl C):41–7.

41.

Verpooten

Giuliano

Verbist

Eestermans

De Broe

. Once-daily dosing decreases renal accumulation of gentamicin and netilmicin. Clin Pharmacol Ther 1989; 45: 22–7.

42.

Gregory

Wells

Pincott

. A comparison of urinary N-acetyl-β-glucosaminidase and α₁-microglobulin excretion with renal tubular morphology, and observation on their clinical significance. J Pharm Med 1993; 3: 15–23.

43.

Calandra

Zinner

Viscoli

Bock

Gaya

Meunier

. Efficacy and toxicity of single daily doses of amikacin and ceftriaxone versus multiple daily doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia. Ann Intern Med 1993; 119: 584–93.